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extracellular and transmembrane domains of human CD34 were
fused in frame to the entire coding region of HSV-tk (CD34-tk).
In this study, we developed a new model for xenogenic GvHD
using immunodeﬁcient NOD SCID 2M null mice (2) and eval-
uated the ability of ganciclovir (GCV) to prevent GvHD after
infusion of CD34-tk-modiﬁed human T cells (Td). Sublethally
irradiated (250 cGy) 2 mice injected retro-orbitally (ro) with
human PBMCs (107T cells; n11) or human T cells (HuT; 107;
n14) had 19% HuT engraftment after 2–3 weeks with an OS of
75% and 25%, respectively, at 5 weeks (p0.006). These mice lost
20% of their body weight and had extensive HuT inﬁltration in
the spleen, liver, lung and kidney. On day 10 and before the start
of any clinical signs of GvHD, mice that went on to develop lethal
GvHD had a 10–15 fold increase in the expression of the HuT
activation markers CD25, CD30, and CD69 in blood (p
0.0005)
and tissues, and a 128-fold increase in serum levels of IFN (5150
pg/ml vs 40 pg/ml) compared to mice that did not develop GVHD.
To generate CD34-tk-modiﬁed human T cells, PBMCs were ac-
tivated with anti-CD3 and anti-CD28 mAbs immobilized on mag-
netic beads (Xcyte™ Dynabeads) in the presence of IL-2 (50
U/mL). After 2 days, cells were incubated with 293 GPG-derived
VSV-G pseudotyped CD34-tk oncoretroviral supernatants for 6 h
at 37C. Td cells were then expanded for 2 more days and isolated
by MACS (Miltineyi Biotech; Td60%). Td cells were puriﬁed to
94% by CD34 immunomagnetic selection using a VarioMACS
magnetic cell separator. Naive T cells (n2), activated non-Td T
cells (Act; n3) and Td and selected T cells (n6) were then
injected ro into 250 cGy conditioned 2 mice. Animals receiving
Td cells were then either left untreated or treated with GCV (1
mg/day, ip) from days 1–7. Mice that received naive T cells died of
lethal GvHD on day 15. Mice that received Act or Td HuT had an
average engraftment of 16% and 34%, respectively, at 3 weeks
post-infusion but did not develop GvHD. We were able to dem-
onstrate that Td T cells could be efﬁciently eliminated in vivo by
treatment with GCV. In conclusion, this xenograft model provides
a unique opportunity for preclinical testing of the CD34-tk/GCV
suicide gene system as well as other methods of GvHD control.
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HUMAN LANGERHANS CELLS IN TRANSPLANTATION: RECIPIENT
CELLS SURVIVE CONDITIONING BUT DONOR CELLS PREDOMINATE AT
DAY 100
Collin, M.P.1; Booth, T.1; Middleton, P.G.1; Jackson, G.H.1; Mackin-
non, S.2; Cook, G.3; Cavet, J.4; Wang, X.N.1; Dickinson, A.M.1 1.
University of Newcastle, Newcastle-upon-Tyne, United Kingdom; 2.
Royal Free Hospital and University College, London, United Kingdom;
3. St. James’s University Hospital, Leeds, United Kingdom; 4. Christie
Hospital, Manchester, United Kingdom.
Graft versus host disease (GvHD) is mediated by donor lympho-
cytes responding to recipient antigens. Recent murine studies have
highlighted the role of recipient antigen-presenting cells (APC) in
triggering acute GvHD. In humans, the fate of recipient APC after
transplantation is largely unknown but persistent recipient cells are
thought to increase the toxicity of early donor lymphocyte infusion
(DLI) and contribute to delayed acute GvHD after immunosup-
pression withdrawal following reduced intensity conditioning. We
have studied Langerhans Cells (LC) in human transplantation
using confocal microscopy to measure cell density in the epidermis.
We have also determined the origin of LC migrating in vitro from
epidermal sheets derived from clinical skin biopsies taken at day
100 post-transplant. In sex-mismatched donor-recipient pairs,
combined Giemsa-FISH X/Y allows precise cell identiﬁcation and
quantitation, unlike in situ techniques. We have studied 144 biop-
sies from over 50 patients conditioned with myeloablative or re-
duced intensity regimens and transplanted from related or unre-
lated donors from pretransplant to 1 year post transplant. LC
genotype has been examined at day 100 in 12 patients. Pretrans-
plant, LC density is not signiﬁcantly different to normal skin
(645 	 273 cells/mm2 vs 705 	 94 cells/mm2). At Day 0, LC
density falls to 593 	 143 cells/mm2 (p 
 0.05) but there is no
difference between myeloablative and reduced intensity condition-
ing. Alemtuzumab conditioning has no signiﬁcant impact. LC
nadir is at 3 weeks, 1 week after neutrophil nadir and 2 weeks after
monocyte nadir. Normal LC density is recovered by day 100 and
exceeds pretransplant density (822	 332 cells/mm2; p
 0.05). LC
recovered from patient biopsies at day 100 show donor predomi-
nance (95%) if the patient is fully engrafted (95% donor in
whole blood; 10/12 patients). In contrast to murine experiments,
the absence of GvHD after T cell depletion (4/12 patients) does
not confer an increased number of recipient cells. Recipient cells
are only preserved when there is signiﬁcant partial donor multi-
lineage chimaerism (2/12 patients). These results support a role for
recipient APC in early acute GvHD as more than two-thirds of
recipient cells survive conditioning. However, recipient APC do
not persist for long periods after transplantation unless there is
signiﬁcant partial chimaerism overall. The role of recipient APC
late GvHD effects must therefore be questioned.
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THE CONTRIBUTION OF CCR1 EXPRESSION ON DONOR LEUKOCYTES
TO THE DEVELOPMENT OF EXPERIMENTAL IDIOPATHIC PNEUMONIA
SYNDROME
Hildebrandt, G.C.1,2; Choi, S.2; Olkiewicz, K.M.2; Corrion, L.A.2;
Chensue, S.W.3; Liu, C.4; Cooke, K.R.2 1. Department of Hematology
and Oncology, BMT Program, University of Regensburg, Regensburg,
Germany; 2. Department of Pediatrics, University of Michigan, Ann
Arbor, MI; 3. Department of Veterans Affairs Medical Center, Ann
Arbor, MI; 4. Department of Pathology, University of Florida College of
Medicine, Gainesville, FL.
Idiopathic Pneumonia Syndrome (IPS) is a severe complication
of allogeneic (allo) bone marrow transplantation (BMT). IPS is
characterized by cellular inﬁltration into the lung that results in
altered pulmonary function and death in the majority of patients.
Leukocyte recruitment during the development of IPS is mediated
by chemokines and their receptors. Speciﬁcally, we have recently
shown an important role for CCL5 (RANTES) in the development
of lung injury following BMT. Receptors for CCL5 include both
CCR5 and CCR1. Although the absence of CCR5 expression has
been shown to worsen GVHD and IPS in some models, the role of
CCR1 in each context remains to be determined. CCR1 is ex-
pressed on a variety of cell types including Th1 lymphocytes,
monocytes and macrophages and contributes to lung injury in a
variety of non-BMT animal models. Using an established mouse
BMT system, we investigated the contribution of CCR1 to exper-
imental IPS. Lethally irradiated B6D2F1 mice received BM and T
cells from syngeneic B6D2F1 or allo B6 CCR1/ donors. Lung
injury developed between 2 and 6 weeks after allo BMT and was
associated with increases in whole lung CCR1 and CCL5 mRNA
expression. Transplantation of CCR1/ donor cells resulted in a
signiﬁcant reduction in IPS severity 6 weeks after BMT as mea-
sured by lung pathology and BAL ﬂuid cellularity, protein content
and TNF levels (Table 1) when compared to allo CCR1/
recipients. Similar differences between groups were also noted at
day 30 (data not shown). CCR1/ BMT also resulted in reduced
systemic GVHD as assessed by survival (92% vs. 50%), clinical
score (1.0	 0.3 vs. 3.0	 0.5) and intestinal injury (index at day 14:
15.8 	 1.8 vs. 23.8 	 1.0) compared to allo controls. In addition,
both splenic T cell expansion (3.7 	 0.4 vs. 9.6 	 0.9  106 cells)
and serum IFN levels (4561 	 559 vs. 10028 	 681 pg/ml) were
signiﬁcantly lower at day 7 following allo BMT with CCR1/
donor cells. In conclusion, our data demonstrate a heretofore
unknown role for CCR1 on donor leukocytes in the development
of IPS and GVHD. Improvement in lung injury observed after
CCR1/ BMT may be attributed to 1) alterations in leukocyte
recruitment to the lung and 2) modulation of donor T cell re-
sponses to host allo-antigens. These data support our previous
ﬁndings that blocking speciﬁc chemokine receptor:ligand interac-
tions may represent novel, non-cross reactive approaches to reduce
deleterious graft-versus host reactions following allo BMT.
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Table 1.
BMT
Group
Path-
ology
Index
BALF Analysis
Total
Cells
( 106)
macs
( 106)
CD8
T Cells
( 103)
GR1
Cells
( 103)
Protein
(g/ml)
TNF
(pg/ml)
Syngeneic 0.7  0.3 0.72  0.15 0.69  0.14 7.2  1.5 7.2  1.5 247  38 0  0
Allo
CCR1/ 5.2  0.8 2.6  0.6 1.9  0.5 473.2  69.3 87.3  14.3 517  58 24.6  1.4
Allo
CCR1/ 2.7  0.6* 1.1  0.1* 0.82  0.1 68.8  7.0** 15.3  1.6** 320  51* 1.0  0.6*
*p 
 0.05; **p 
 0.01; p  0.06.
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REVERSAL OF SEVERE GRAFT-VERSUS-HOST DISEASE AFTER NON-
MYELOABLATIVE MATCHED UNRELATED DONOR STEM CELL TRANS-
PLANT BY INFUSION OF BACKUP AUTOLOGOUS PERIPHERAL BLOOD
STEM CELLS
Khan, S.A.; Moreb, J.S. University of Florida College of Medicine,
Gainesville, FL.
Acute graft vs. host disease (GVHD) is major concern in stem cell
transplantation and is associated with signiﬁcant morbidity and mor-
tality. The incidence of grade II-IV acute GVHD is 78% and grade
III-IV is 36% afterHLAmatched unrelated donor (MUD) transplant.
We report a successful use of infusion of autologous peripheral blood
stem cells to treat severe, refractory grade 4 GVHD after a non-
myeloablative MUD transplant. Patient was a 55 years old white
female with non-secretory MM presenting with pathological fracture
of her arm. She was initially treated with VAD and then hyper-CVAD
chemotherapy and achieved partial remission (PR). Subsequently, she
underwent autologous peripheral blood stem cell transplant (PB-
SCT). She progressed 2 months after autologous PBSCT and became
refractory to Thalidomide as well as chemotherapy combination of
CCNU, VP-16, Cytoxan and prednisone. Therefore, she underwent
a non-myeloablative MUD PBSCT after conditioning with Fludara-
bine, ATG and Busulfan. Post transplant evaluation revealed persis-
tent disease with 60% plasma cells and mixed chimerism with 91%
male donor cells, so immunosuppressive therapy was tapered. Two
weeks later she developed severe grade 3 GVHD involving skin and
gut which progressed to grade 4GVHD and was refractory to therapy
with FK506, Steroids, Cellcept, Daclizumab, Remicade and Thalid-
omide. She developed severe malabsorption with albumin as low as
1.6. We gave her cyclophosphamide followed by backup autologous
stem cells in order to stop the GVHD by creating “host-versus-graft
effect”. On day90 she received 10 106/kg CD34 cells and 1.4
107/KG CD3 cells. Four weeks later she still had 99% donor chi-
merism with no signiﬁcant change in her GVHD symptoms and
therefore she was given 2nd infusion of 42 106/kg CD34 cells and
5.7  107/kg CD3 cells. Subsequently, she recovered slowly from
her GVHD and was discharged after 3 months of hospitalization.
Currently she is 2.5 years post transplant without any immunosup-
pressive therapy and most recent BM test showed 100% donor chi-
merism and stable MM with 10% plasma cells. This case demon-
strates feasibility of infusion of autologous stem cells to control
refractory GVHD. A similar case was previously reported (Ricordi et
al, Cell Transplantation 1994;3:187). The mechanism for such effect
is not clear but may involve development of tolerance of donor T
lymphocytes vs. host without inhibiting GVL effect or causing mixed
chimerism.
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CARDIAC MANIFESTATIONS OF GRAFT-VERSUS-HOST DISEASE
Gilman, A.L.1; Rackley, C.2; Goldman, F.3; Serrano, A.4; Chan, K.W.5;
Schultz, K.R.6 1. University of North Carolina School of Medicine,
Chapel Hill, NC; 2. Children’s Memorial Hospital, Chicago, IL; 3.
University of Iowa, Iowa City, IA; 4. Children’s Mercy Hospital, Kansas
City, MO; 5. M.D. Anderson Cancer Center, Houston, TX; 6. British
Columbia Children’s Hospital, Vancouver, BC, Canada.
Graft-versus-host disease (GVHD) is a major cause of morbidity
and mortality after bone marrow transplantation. Well-docu-
mented manifestations of GVHD include dermatologic, gastroin-
testinal, hepatic, pulmonary, musculoskeletal, and hematologic
manifestations and sicca syndrome. To date, the heart has only
rarely been reported to be a target of GVHD. We report 11
patients who developed bradycardia, coronary artery disease, or
cardiomyolysis in association with acute or chronic GVHD. Eight
patients were male and 3 were female. Patients were 4 months-19
years old (median 12 yrs). Three patients received post-transplant
immunotherapy. The patient with Fanconi anemia/AML received
IL-2 for recurrent leukemia and two recipients of T cell-depleted
grafts received DLI, one for relapse and one for graft rejection.
Regarding possible risk factors, six patients had received total body
irradiation and ﬁve patients had received anthracyclines prior to
transplant. Other possible causes for heart block and bradycardia
including electrolyte abnormalities and medications were excluded.
Of eight patients with bradycardia, seven had resolution of brady-
cardia (including heart block and sinus node failure) and one had
improvement with increased immunosuppression. Three patients
had a recurrence of bradycardia and GVHD following weaning of
immunosuppression. The severity of these manifestations ranged
from asymptomatic to fatal. The incidence of cardiac manifesta-
tions was estimated at 9.3%. TBI and prior anthracycline therapy
did not seem to be signiﬁcant risk factors because approximately
half of patients had not received either. The majority of patients
had alternative donors and 3 had post-transplant immunotherapy.
Although uncommon, it is important to recognize these cardiac
manifestations as they may reﬂect GVHD activity and may be
reversible by increasing immunosuppression.
Cardiac Manifestations of GVHD
Age Disease
Stem Cell
Source GVHD
Cardiac
Manifest-
ation
HR during
Bradycardia
Normal
HR for
Age
Cardiac
Outcome
4 mo SCID Haplo
father
BM
Hyper-
acute
&
chronic
Complete
heart
block
30–40’s 90–140’s Resolved
w/
MP/
CSA
2 yr Fanconi,
AML
MSD BM Atypical,
after
IL-2
for
GVL
Sinus node
failure
30–40’s 90–140’s Resolved
w/
MP/
Tac
18 mo Wiskott-
Aldrich
5/6 MUD
cord
Acute &
chronic
Bradycardia 50–90’s 90–140’s Resolved
w/
MP/
HCQ
21 mo CID 4/6 MUD
cord
Acute &
chronic
Bradycardia 50–80’s 90–140’s Improved
w/
MP/
Pento-
ostatin
13 yr Refractory
LCL
MSD
PBSC
Acute &
chronic
Bradycardia 50’s 60–110 Resolved
w/
MP
17 yr ALL, CR4 6/6 MUD
PBSC
Acute Bradycardia 50’s 60–110 Resolved
w/
MP/
Zena-
pax
12 yr ALL, CR3 Haplo
mother
PBSC
Acute &
chronic
Bradycardia 50–60’s,
low 40
60–110 Resolved
w/
MP
13 yr MDS,
AML
Haplo
mother
PBSC
Acute &
chronic
Bradycardia 50–60’s 60–110 Resolved
w/
MP
18 yr ALL, CR3 MSD
PBSC
Acute &
chronic
Cardiomy-
olysis
— — Sudden
death
19 yr AML,
relapse
MSD BM Acute &
chronic
Coronary
arterioscler-
osis
— — Sudden
death
25 mo Wiskott-
Aldrich
6/6 MUD
BM
Acute &
chronic
Coronary
arterioscler-
osis
— — Sudden
death
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RELATIONSHIP BETWEEN RACE AND RISK OF ACUTE GRAFT-VERSUS-
HOST DISEASE
Klumpp, T.R.; Jillella, A.P.; Ulicny, J.A.; Emmons, R.V.B.; Mangan,
K.F. Fox Chase-Temple BMT Program, Philadelphia, PA.
Several groups have reported an increased incidence of acute
GVHD among African-American transplant recipients. However,
informal communications with other BMT teams suggest that
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